Results 71 to 80 of about 8,519 (204)

PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer

Frontiers in Immunology, 2022
Protein arginine transferase 5 (PRMT5) has been implicated as an important modulator of tumorigenesis as it promotes tumor cell proliferation, invasion, and metastasis. Studies have largely focused on PRMT5 regulating intrinsic changes in tumors; however,
Rui Hu, Bingqian Zhou, Zheyi Chen, Shiyu Chen, Ningdai Chen, Lisong Shen, Lisong Shen, Lisong Shen, Haibo Xiao, Yingxia Zheng   +9 more
doaj   +1 more source

The Maternal Blood Transcriptome Reflects Molecular Signatures Associated With Large Offspring Syndrome and Other Adverse Pregnancy Outcomes in Cattle

The FASEB Journal, Volume 40, Issue 20, 31 October 2026.
Blood samples from pregnant heifers carrying in vitro‐produced embryos were analyzed for RNA‐sequencing to test whether maternal blood transcriptome could be predictive of large offspring syndrome, stillbirth, and abortion compared with controls.
Tatiane S. Maia, Maria B. Rabaglino, Rebecca Krisher, Paula Rodriguez‐Villamil, Jeniffer Pamela J. Laguna, Jeniffer F. Escoto, Yanping Zhang, Abigail J. Sproull, Peter J. Hansen   +8 more
wiley   +1 more source

Zebrafish prmt5 arginine methyltransferase is essential for germ cell development

, 2019
Protein arginine methyltransferase 5 (Prmt5), a type II arginine methyltransferase, symmetrically dimethylates arginine in nuclear and cytoplasmic proteins.
Liu, Xing, Zhang, Dawei, Cai, Xiaolian, Rong, Fangjing, Ouyang, Gang, Zhu, Junji, Yu, Guangqing, Wang, Jing, Xu, Chenxi, Xiao, Wuhan   +9 more
core   +1 more source

Identification of PRMT5 as a therapeutic target in cholangiocarcinoma [PDF]

Cholangiocarcinoma (CCA) remains a highly aggressive malignancy characterized by poor prognosis and limited response to standard therapies, despite recent advances in drug discovery.
MARIANI, STEFANO
core   +2 more sources

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, Volume 20, Issue 10, Page 2533-2566, October 2026.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes

Cell Reports, 2018
Summary: Protein arginine methyltransferase 5 (PRMT5) is overexpressed in many cancer types and is a promising therapeutic target for several of them, including leukemia and lymphoma.
Pierre-Jacques Hamard, Gabriel E. Santiago, Fan Liu, Daniel L. Karl, Concepcion Martinez, Na Man, Adnan K. Mookhtiar, Stephanie Duffort, Sarah Greenblatt, Ramiro E. Verdun, Stephen D. Nimer   +10 more
doaj   +1 more source

UFL1‐Mediated UFMylation of ENO1 Restrains Aerobic Glycolysis and Colorectal Cancer Progression

Advanced Science, Volume 13, Issue 59, 23 October 2026.
UFMylation restrains aerobic glycolysis and colorectal cancer progression by modifying the glycolytic enzyme ENO1. Pharmacological enhancement of the UFL1–ENO1 interaction by the FDA‐approved antibiotic torezolid promotes ENO1 UFMylation, suppresses tumor metabolism, and sensitizes colorectal cancer to chemotherapy, revealing an actionable metabolic ...
Xiuqing Ma, Rui Wan, Yueyuan Zhong, Ziyang Cui, Xuan Zhang, Xiaoqiang He, Rong Wang, Lei Huang, Wan‐Yang Sun, Rong‐Rong He, Yang Zhou, Jianshuang Li, Li Shen, Shao‐Hua Wang, Tongzheng Liu   +14 more
wiley   +1 more source

Silencing PRMT5 or p44 expression inhibited the growth of prostate cancer cells.

, 2012
(A) The shRNA-mediated silencing of PRMT5 or p44 expression in prostate cancer cells. Western blot analysis of whole-cell lysates made from LNCaP cells infected with lentivirus expressing the non-target (NT) shRNA (lanes 1, 5), PRMT5 (lanes 2–4), or p44 (
Zhongping Gu (144275), Chidan Wan (144282), Tao Liu (10785), Peng Lee (144280), Zhengxin Wang (144284), Yirong Li (144277)   +5 more
core   +1 more source

H3K9me3 inhibition reverses Alzheimer's progression by restoring synaptic and immune proteostasis across the brain–retina axis

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract INTRODUCTION Epigenetic dysregulation is increasingly linked to aging and neurodegeneration, yet its contribution to retinal and brain pathology in Alzheimer's disease (AD) remains unclear. METHODS We quantified the repressive epigenetic mark histone H3 lysine 9 trimethylation (H3K9me3) in post mortem retinas and brains from donors spanning ...
Dieu‐Trang Fuchs, Jean‐Philippe Vit, Altan Rentsendorj, Yosef Koronyo, Julia Sheyn, Bhakta Prasad Gaire, Saba Shahin, Haoshen Shi, Oksana Chepurna, Miyah R. Davis, Jered W. Wilson, Stuart L. Graham, Vivek K. Gupta, Lon S. Schneider, Michael T. Kleinman, Tao Sun, Margaret Fahnestock, David A. Horne, Mehdi Mirzaei, Keith L. Black, Maya Koronyo‐Hamaoui   +20 more
wiley   +1 more source

Targeting the DNA Damage Response in Cancer

MedComm, Volume 7, Issue 10, October 2026.
Targeting the DNA damage response (DDR) reshapes both tumor vulnerability and antitumor immunity. DNA lesions and DDR inhibitors can promote cytosolic nucleic‐acid sensing, antigen presentation, and immune activation, but can also induce adaptive immune escape.
Yihuan Qiao, Boyu Kang, Jian Zhang, Rui Zhang, Jipeng Li   +4 more
wiley   +1 more source